DRG Market Assessment reports

Clarivate Epidemiology’s coverage of Friedreich’s ataxia comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…

Clarivate Epidemiology’s coverage of cerebral adrenoleukodystrophy comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…

Parkinson’s disease is a chronic neurodegenerative disease characterized by progressively worsening motor symptoms. Treatment of Parkinson’s disease in China comprises a broad range of…

Core to Parkinson’s disease (PD) treatment is the co-prescription of various formulations of the gold-standard SOC levodopa with a range of adjunctive therapies from other drug classes (e.g.,…

Clarivate Epidemiology’s coverage of neuromyelitis optica spectrum disorder (NMOSD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the…

For neurologists, established molecules like leveteriacetam, lamotrigine, and carbamazepine remain the first choice of treatment for epilepsy; however, the new entrants in the market are evoloving…

Since 2015, eight new brands have launched into the highly generic U.S. Parkinson’s disease (PD) therapy market, and six more are expected to launch soon. Chronic polypharmacy and progressive…

An increasing number of clinically unique immunomodulatory disease-modifying therapies (DMTs) are approved for the treatment of relapsing forms of multiple sclerosis (MS), the most prevalent form…

Cervical dystonia (CD), is a rare neurological disorder that mostly affects middle-aged adults, with an average age of symptom onset of 50 years. Given the rarity of the condition and symptomatic…

Spasticity is characterized by an increase in muscle tone and is highly prevalent among patients diagnosed with some neurological conditions (e.g., stroke, multiple sclerosis [MS], spinal cord…